AI assistant
Vaxcyte, Inc. — Director's Dealing 2022
Sep 7, 2022
31100_dirs_2022-09-07_ae9d5643-b6cd-46dd-97a8-3644823a42b1.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2022-09-02
Reporting Person: Fairman Jeff (VP, Research)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-09-02 | Common Stock | F | 519 | $26.38 | Disposed | 17143 | Direct |
| 2022-09-06 | Common Stock | S | 4664 | $26.5381 | Disposed | 301563 | Indirect |
| 2022-09-06 | Common Stock | S | 336 | $27.1382 | Disposed | 301227 | Indirect |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 50000 | Indirect |
Footnotes
F1: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of restricted stock units.
F2: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan.
F3: The price reported is a weighted-average price. The shares were sold at prices ranging from $26.04 to $27.075. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F4: The price reported is a weighted-average price. The shares were sold at prices ranging from $27.09 to $27.23. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.